MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
May 09, 2022 07:00 ET
|
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab Higher rates of complete skin clearance were...
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.
April 05, 2022 12:17 ET
|
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp. MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with...